Management of Atypical Renal Cell Carcinomas

  • Bobby C. Liaw
  • Reza Mehrazin
  • Charles Baker
  • John P. Sfakianos
  • Che-Kai Tsao
Genitourinary Cancers (W Oh and M Galsky, Section Editors)
First Online:
  • 311 Downloads
Part of the following topical collections:
  1. Topical Collection on Genitourinary Cancers

Opinion statement

Non-clear cell renal cell carcinoma (RCC) encompasses a diverse group of diseases, with research yielding different histologic findings and genetic profiles with each distinct subgroup. Simply mirroring the management techniques of clear cell RCC and borrowing from its growing armamentarium of therapeutic agents, while somewhat productive at first, but will ultimately be limiting. Further investigation into the molecular pathogenesis of disease, similarities and differences between specific subtypes, and mechanisms of resistance to therapeutics will help identify new targets, stimulate development of novel agents, and improve clinical trial offerings for non-clear cell RCC (nccRCC). As nccRCC has been largely excluded from past trials, there will be a need for future trials to be designed either to evaluate nccRCC specifically, or to include nccRCC as a prespecified subgroup. Multi-center collaborative trials should be supported, as many of the nccRCC subtypes are rare and remain underrepresented even within the construct of trials that only enroll nccRCC. Given the absence of clear molecular targets at present, patients with metastatic nccRCC should be offered and encouraged enrollment on clinical studies whenever possible.

Keywords

Renal cell carcinoma Non-clear cell Atypical Papillary Chromophobe Kidney cancer 
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Miller KD, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol. 2013;23(1):46–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6 Pt 1):2353–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am. 2012;39(2):119–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Algaba F, et al. Current pathology keys of renal cell carcinoma. Eur Urol. 2011;60(4):634–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Bugert P, et al. Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Investig. 1997;76(2):203–8.PubMedGoogle Scholar
  8. 8.
    Foot NC, Papanicolaou GN. Early renal carcinoma in situ detected by means of smears of fixed urinary sediment. J Am Med Assoc. 1949;139(6):356–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Polascik TJ, Bostwick DG, Cairns P. Molecular genetics and histopathologic features of adult distal nephron tumors. Urology. 2002;60(6):941–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Selli C, et al. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol. 1997;158(1):245–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Kobayashi N, et al. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39(9):1350–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Schaeffer EM, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106(1):62–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Falzarano SM, et al. Renal cell carcinoma occurring in patients with prior neuroblastoma: a heterogenous group of neoplasms. Am J Surg Pathol. 2016;40(7):989–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Schimke RN, Collins DL, Stolle CA. Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. Am J Med Genet A. 2010;152A(6):1531–5.PubMedGoogle Scholar
  16. 16.
    Huimiao J, et al. Mucinous tubular and spindle cell carcinoma of the kidney: diagnosis by fine needle aspiration and review of the literature. Cytojournal. 2015;12:28.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Zhang Y, et al. Mucinous tubular and spindle cell carcinoma and solid variant papillary renal cell carcinoma: a clinicopathologic comparative analysis of four cases with similar molecular genetics datum. Diagn Pathol. 2014;9:194.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Klatte T, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol. 2012;137(5):761–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Cheng X, et al. Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. BMC Urol. 2016;16(1):40.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Macher-Goeppinger S, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012;25(2):308–15.PubMedGoogle Scholar
  21. 21.
    Zhou M, et al. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol. 2009;33(12):1840–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhao M, et al. Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature. Int J Clin Exp Pathol. 2015;8(9):11124–31.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Srigley JR, et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37(10):1469–89.PubMedCrossRefGoogle Scholar
  24. 24.
    Chen F, et al. Clinical characteristics and pathology of thyroid-like follicular carcinoma of the kidney: report of 3 cases and a literature review. Mol Clin Oncol. 2016;4(2):143–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Gill AJ, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–602.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Williamson SR, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol. 2015;28(1):80–94.PubMedCrossRefGoogle Scholar
  27. 27.
    Ozluk Y, et al. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. Hum Pathol. 2015;46(12):1951–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Schmidt L, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Isaacs JS, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8(2):143–53.PubMedCrossRefGoogle Scholar
  30. 30.
    de Velasco G, et al. Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): case report and review of the literature. Can Urol Assoc J. 2015;9(3–4):E243–6.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    • Haas NB, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008–16. Randomized phase III study evaluating benefit of adjuvant sunitinib or sorafenib in high-risk non-metastatic RCC, suggesting lack of benefit in subset analysis of nccRCC.Google Scholar
  32. 32.
    Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer. 2008;113(10):2671–80.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.PubMedCrossRefGoogle Scholar
  35. 35.
    Choueiri TK, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Kassouf W, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007;178(5):1896–900.PubMedCrossRefGoogle Scholar
  37. 37.
    Shuch B, et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology—is up-front resection indicated and, if not, is it avoidable? J Urol. 2009;182(5):2164–71.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    • Aizer AA, et al. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014;113(5b):E67–74. Retrospective analysis of SEER database suggesting clinical benefit of cytoreductive nephrectomy in nccRCC across all histologic subtypes.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Vera-Badillo FE, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015;67(4):740–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Oudard S, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol. 2007;177(5):1698–702.PubMedCrossRefGoogle Scholar
  41. 41.
    Milowsky MI, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002;94(1):111–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Gollob JA, et al. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology. 2001;58(6):1058.PubMedCrossRefGoogle Scholar
  43. 43.
    Pecuchet N, et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol. 2013;24(12):2963–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Walsh A, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2010;55(6):1217–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Maroja Silvino MC, et al. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 2013;5(3):e44.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Haas NB, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012;29(2):761–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Escudier B, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959–61.PubMedCrossRefGoogle Scholar
  48. 48.
    Upton MP, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28(5):488–95.PubMedCrossRefGoogle Scholar
  49. 49.
    Motzer RJ, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–81.PubMedCrossRefGoogle Scholar
  50. 50.
    •• Armstrong AJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88. Randomized phase II study of first-line sunitinib vs. everolimus in nccRCC which demonstrates PFS benefit and improved ORR, the basis for which VEGF-directed therapy is preferentially given in the first line.PubMedCrossRefGoogle Scholar
  51. 51.
    • Tannir NM, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–74. Randomized phase II study of first-line sunitinib vs. everolimus, with crossover at progression, suggesting PFS and ORR benefit with first-line sunitinib.PubMedCrossRefGoogle Scholar
  52. 52.
    • Motzer RJ, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–72. Randomized phase II study of sunitinib vs. everolimus, with crossover at progression, showing insignificant trend towards PFS benefit with front-line sunitinib in subgroup of nccRCC patients.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    • Ravaud A, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)dagger. Ann Oncol. 2015;26(6):1123–8. Phase II study of first-line sunitinib for papillary RCC, showing activity in both type 1 and type 2 disease.PubMedCrossRefGoogle Scholar
  54. 54.
    Choueiri TK, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127–31.PubMedCrossRefGoogle Scholar
  55. 55.
    Golshayan AR, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Kyriakopoulos CE, et al. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. 2015;13(2):e79–85.PubMedCrossRefGoogle Scholar
  57. 57.
    • Haas NB, et al. ECOG 1808: randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features. J Clin Oncol. 2016;34(suppl; abstr 4511):4511. Largest prospective randomized trial for sarcomatoid RCC to date. Phase II study of sunitinib plus gemcitabine vs. sunitinib for which preliminary data suggests a role for adding chemotherapy to targeted therapy for sarcomatoid RCC.Google Scholar
  58. 58.
    Srinivasan R, et al. Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib. Eur J Cancer. 2014;50(Supplement 6):8.CrossRefGoogle Scholar
  59. 59.
    Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.PubMedCrossRefGoogle Scholar
  60. 60.
    Dutcher JP, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–9.PubMedCrossRefGoogle Scholar
  61. 61.
    • Voss MH, et al. Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2016;34:3846–53. Phase II study of everolimus plus bevacizumab in nccRCC, notable for better ORR associated with disease with papillary features.CrossRefGoogle Scholar
  62. 62.
    Mahoney KM, et al. Phase 2 study of Bevacizumab and Temsirolimus after VEGFR TKI in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2016;14(4):304–13. e6 Google Scholar
  63. 63.
    Choueiri TK, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–84.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    • McDermott DF, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34(8):833–42. Phase I trial of atezolizumab for metastatic nccRCC.PubMedCrossRefGoogle Scholar
  65. 65.
    Gherardi E, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.PubMedCrossRefGoogle Scholar
  66. 66.
    Graveel, C.R., D. Tolbert, and G.F. Vande Woude. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol. 2013. 5(7).Google Scholar
  67. 67.
    Li Y, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28(39):3442–55.PubMedCrossRefGoogle Scholar
  68. 68.
    Axelrod H, Pienta KJ. Axl as a mediator of cellular growth and survival. Oncotarget. 2014;5(19):8818–52.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Birchmeier C, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25.PubMedCrossRefGoogle Scholar
  70. 70.
    Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002;109(7):863–7.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Zhao H, et al. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation. Cancer Biol Ther. 2016;11:1–9.CrossRefGoogle Scholar
  72. 72.
    • Choueiri TK, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6. Phase II single-arm study of foretinib, a dual MET and VEGF inhibitor, showing limited activity in papillary RCC, but notable to have significant response for disease with germline MET mutation.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Bobby C. Liaw
    • 1
  • Reza Mehrazin
    • 2
  • Charles Baker
    • 1
  • John P. Sfakianos
    • 2
  • Che-Kai Tsao
    • 1
  1. 1.Division of Hematology and Medical OncologyThe Tisch Cancer Institute, Icahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of UrologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations